Biden sets COVID-19 vaccine rules for businesses, prompting Republican backlash
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Pfizer's (PFE) COVID Pill Best in Class, Will Put Pressure on Merck (MRK) and Regeneron (REGN) - Analyst
November 5, 2021 8:47 AM EDT(Updated - November 5, 2021 8:54 AM EDT)
Earlier today, Pfizer Inc. (NYSE: PFE) announced its investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR study of non-hospitalized adult patients with COVID-19,... More
Pfizer's (PFE) COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
November 5, 2021 6:45 AM EDTPfizer Inc. (NYSE: PFE) today announced its investigational... More
